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Abstract 
Background: Nonunion is a failure of healing following a bone fracture. Its physiopathology remains partially unclear 
and the discovery of new mediators could promote the understanding of bone healing.
Methods: Thirty‑three atrophic nonunion (NU) patients that failed to demonstrate any radiographic improvement 
for 6 consecutive months were recruited for providing serum samples. Thirty‑five healthy volunteers (HV) served as 
the control group. Proteomics studies were performed using SELDI‑TOF–MS and 2D‑DIGE approaches, associated or 
not with Proteominer® preprocessing, to highlight biomarkers specific to atrophic nonunion pathology. Peak intensi‑
ties were analyzed by two statistical approaches, a nonparametric Mann–Whitney U tests (univariate approach) and 
a machine‑learning algorithm called extra‑trees (multivariate approach). Validation of highlighted biomarkers was 
performed by alternative approaches such as microfluidic LC–MS/MS, nephelometry, western blotting or ELISA assays.
Results: From the 35 HV and 33 NU crude serum samples and Proteominer® eluates, 136 spectra were collected by 
SELDI‑TOF–MS using CM10 and IMAC‑Cu2+ ProteinChip arrays, and 665 peaks were integrated for extra‑trees multi‑
variate analysis. Accordingly, seven biomarkers and several variants were identified as potential NU biomarkers. Their 
levels of expression were found to be down‑ or up‑regulated in serum of HV vs NU. These biomarkers are inter‑α‑
trypsin inhibitor H4, hepcidin, S100A8, S100A9, glycated hemoglobin β subunit, PACAP related peptide, complement 
C3 α‑chain. 2D‑DIGE experiment allowed to detect 14 biomarkers as being down‑ or up‑regulated in serum of HV vs 
NU including a cleaved fragment of apolipoprotein A‑IV, apolipoprotein E, complement C3 and C6. Several biomarkers 
such as hepcidin, complement C6, S100A9, apolipoprotein E, complement C3 and C4 were confirmed by an alterna‑
tive approach as being up‑regulated in serum of NU patients compared to HV controls.
Conclusion: Two proteomics approaches were used to identify new biomarkers up‑ or down‑regulated in the non‑
union pathology, which are involved in bone turn‑over, inflammation, innate immunity, glycation and lipid metabo‑
lisms. High expression of hepcidin or S100A8/S100A9 by myeloid cells and the presence of advanced glycation end 
products and complement factors could be the result of a longstanding inflammatory process. Blocking macrophage 
activation and/or TLR4 receptor could accelerate healing of fractured bone in at‑risk patients.
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Background
Five to ten percent of fractures do not consolidate spon-
taneously after plaster cast immobilization or surgical 
intervention. Unconsolidated fractures are defined as 
nonunion fractures that have not made any progression 
toward healing 6 months after the fracture-related injury. 
Nonunion fracture represents a major socioeconomic 
issue mainly affecting young population and being par-
ticularly debilitating.
Two main forms of radiographic nonunion exist: 
atrophic nonunion for which there is no evidence of cal-
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nonunion for which there is abnormal callus formation. 
Atrophic nonunion result from a failure of normal cel-
lular response necessary for bone reconstruction [1]. 
Several studies have demonstrated that the pool of bone 
marrow-derived mesenchymal stem cells (hMSCs) in 
nonunions was decreased and their proliferation delayed 
[1–3]. However, once committed, hMSCs from nonun-
ions were able to proliferate, differentiate into osteoblas-
tic cells and mineralize in  vitro as efficiently as hMSCs 
from healthy subjects [2]. Hypertrophic nonunion would 
rather appear following instability at the site of fracture. 
Poorly vascularized bones as scaphoid hand, talus, tibia, 
ulna or hip seem to be more often the seat of nonunion. 
Angiogenesis is necessary to promote revascularization 
of the injured site. New vessels enhance mobilization of 
osteoprogenitor cells and of growth factors involved in 
osteogenesis.
Risk factors for nonunion can be divided as patient-
dependent factors (tobacco use, alcohol abuse, NSAID, 
malnutrition, diabetes, vascular disease, previous radia-
tion therapy, hypothyroidism and vitamin D deficiency) 
or patient–independent factors (comminution, poor 
cortical apposition, interposed soft tissue, soft tissue 
damage, bone loss, quality of surgical treatment and 
infection) [4]. However, biological mediators can also 
be causative factors of nonunion. Several bone turno-
ver markers such as bone-specific alkaline phosphatase 
[5–8], osteocalcin [5, 6, 9] and fragments of type-I and 
type-III procollagen [7] have been suggested as poten-
tial markers of nonunion. Levels of leptin, interleukin-6, 
platelet-derived growth factor-BB, stem cell factor and 
insulin-like growth factor-1 were found altered in nonun-
ion compared to healthy volunteers [2]. Osteoprotegerin 
serum level was increased in atrophic nonunion shaft 
fractures [10].
Today there is a real need for a better understanding 
of the physiology and pathophysiology of nonunion to 
develop new minimally invasive therapeutics for bone 
reconstruction that do not present the side effects of con-
ventional surgical techniques while achieving equivalent 
benefits. Proteomics is an interesting approach to search 
for new protein involved in nonunion pathology. Surface-
enhanced laser desorption/ionization time of flight mass 
spectrometry (SELDI-TOF–MS) and two-dimensional 
difference gel electrophoresis (2D-DIGE) techniques are 
both complementary for biomarker search, investigat-
ing 1–30 and 20–200  kDa protein mass range, respec-
tively. SELDI ProteinChip array surfaces include a set 
of classic chromatographic chemistries for capturing 
proteins according to their physico-chemical proper-
ties and displaying various protein profiles from an indi-
vidual biological sample [11]. The principle of 2D-DIGE 
comparative proteomic analyses relies on the separation 
of proteins by 2D gel electrophoresis and comparison of 
proteins levels using different fluorescent dyes [12]. For 
both methods, high or low abundance protein signals are 
flagged for consideration as potential biomarkers of non-
union disease, while proteins in serum that give similar 
signals in nonunion and in controls are ignored. Our goal 
with the present study was to identify biomarkers asso-
ciated with non-healing bone fractures in a nonunion 
atrophic population using an exploratory, observational, 
retrospective, cohort study design. The discovery of a set 
of new mediators could serve as a bridge between clinical 
and laboratory procedures and promote a better under-
standing of the physiopathology of bone healing.
Methods
Healthy volunteers (n = 35) and nonunion patients 
(n = 33)
Thirty-three atrophic nonunion (NU) patients were 
recruited through hospital outpatient clinics. All atrophic 
nonunion patients fulfilled established diagnostic criteria 
as described in [13] and failed to demonstrate any radio-
graphic improvement for 6 consecutive months. Thirty-
five healthy volunteers (HV) served as the control group. 
Epidemiologic data of HV and NU patients are summa-
rized in Table 1. All subjects were qualified for entry into 
the study considering the following exclusion criteria: 
septic nonunion, head injury, diseases that might inter-
fere with bone metabolism such as renal insufficiency, 
liver diseases, systemic inflammation (CRP  >  0.5  mg/
dL), osteoporosis and malabsorption. The study proto-
col was approved by the local institutional review boards 
of CHU Hospital of Liège (Research Ethics Commit-
tee—human protocol #2005-020—Principal Investiga-
tor: Prof M. Malaise). The bone sites of nonunion were: 7 
radius, 5 humerus, 2 fibula, 2 scaphoids, 3 ulna, 3 meta-
tarsus, 1 iliac bone, 3 clavicles, 2 femur and 5 tibia. The 
mean time (±standard deviation—SD) from the fracture 
related injury was 19 ± 9 months. All HV did not expe-
rience any fracture except two who broke a small bone 
and reconsolidated correctly 1 year prior to the inclusion 
in the study. All patients in the nonunion groups were 
on non-steroid anti-inflammatory drugs and analgesics 
such paracetamol (at a dose <4 g/day) or tramadol (at a 
dose <150 mg/day). One-third of the patients were taking 
anxiolytics such as alprazolam (at a dose <1 mg/day). HV 
were not taking any treatment.
Serum processing
Blood samples were allowed to coagulate in plain glass 
tubes during 30–60  min. Serum was obtained by cen-
trifugation at 2800 rpm for 10 min, aliquoted and imme-
diately frozen at −80  °C until required for proteomics 
analysis.
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Proteominer®
The use of hexapeptide libraries (ProteoMiner®, Biorad 
Laboratories Inc., Hercules, CA, USA) can significantly 
increase the detection of medium- and low-abundance 
proteins by the partial removal of high abundance pro-
teins [14]. Proteominer® treatment was therefore applied 
to the entire cohort of serum samples. All serum samples 
were processed in 5  days according to manufacturer’s 
instructions. After removal of unbound fraction with PBS 
buffer (3  ×  5  min of incubation), proteins were eluted 
with 3 × 100 µl of 25 mM Tris, 7 M urea, 2 M thiourea, 
4  % CHAPS. A quality control (serum provided from a 
healthy volunteer) was run throughout the 5 days of Pro-
teominer® process to control the reproducibility across 
the time. It is presented in Additional file  1: Appendix 
Figure 1.
SELDI‑TOF–MS
The 68 serum samples were loaded in duplicates as crude 
serum samples or Proteominer® eluate on two types 
of ProteinChip arrays: an anionic array (CM10) and an 
immobilized metal affinity capture bound with Cu2+ 
(IMAC-Cu) in order to capture a larger range of potential 
biomarkers. Four experimental conditions were there-
fore used in this study: (1) crude serum on CM10 arrays 
(pH9); (2) crude serum on IMAC-Cu2+ arrays; (3) Prot-
eominer® eluate on CM10 (pH9) and (4) Proteominer® 
eluate on IMAC-Cu2+ arrays.
Crude serum samples were first denatured within 1.5 
volume of 7 M urea, 2 M thiourea, 2 % CHAPS in 50 mM 
Tris buffer, and then diluted in six volumes of the follow-
ing binding buffers: 100 mM Tris, pH9 (for CM10 arrays) 
or 100  mM phosphate buffer, 0.5  M NaCl, pH 7.6 (for 
IMAC-Cu2+ arrays). Proteominer® eluates were tenfold 
diluted in their corresponding binding buffers (see crude 
serum).
ProteinChip arrays were prepared according to manu-
facturer’s instructions and as previously described in 
[15]. Briefly, IMAC-Cu2+ arrays were successively incu-
bated with 2 ×  10  µL of CuSO4, rinsed with H2O, then 
incubated with 0.1  M acetate buffer (pH4) and finally 
rinsed with H2O. Then, CM10 and IMAC-Cu2+ arrays 
were equilibrated with 2  ×  10  µL of binding buffer for 
5  min. Ten microliters of each diluted serum (crude or 
eluate) mixture was applied, in duplicate, on the Pro-
teinChip array and incubated for 1  h at room tempera-
ture. After discarding any remaining sample, arrays were 
washed three times with 10 µL of their respective bind-
ing buffer for 5 min, and then briefly rinsed with distilled 
water. Chips were air-dried and stored in the dark at 
Table 1 Demographic and clinical characteristics of healthy control and nonunion patients used in the study
P value (quantitative data): Mann-Whitney test
P value (qualitative data): Yates’continuity corrected χ2
HV healthy volunteers; NU nonunions; NIDDM noninsulin-dependent diabetes mellitus
HV NU P values
n 35 33
Age [median (range)] 32 (23–78) 44 (18–78) 0.004
Sexe (% of female) 62 % 31 % 0.003
BMI [median (range)] 26.1 (20.5–31.1) 26.8 (18.8–37.1) NS
Smokers 28 % 58 % 0.03
Daily alcohol 0 % 29 % 0.003
Comorbidities
Fracture history in the past year of visit 6 % 100 % <0.001
Rheumatic diseases (osteoarthritis, psoriatic arthritis and rheumatoid arthritis) 0 % 14 % NS
Gastric (heartburn and esophagitis) 0 % 14 % NS
Diabetes (NIDDM) 0 % 10 % NS
Pulmonary (asthma, emphysema, chronic pulmonary disease, pneumothorax) 0 % 24 % 0.006
Cardiovascular (ischaemia, deep vein thrombosis, infarction) 0 % 14 % NS
High blood pressure 0 % 17 % NS
Hypercholesterolemia 0 % 17 % NS
Hypothyroidism 0 % 0 % NS
Hypovitamin D 0 % 3 % NS
Treatment
NSAID and/or analgesic and/or tramadol 0 % 100 % <0.001
Anxiolytics 0 % 33 % <0.001
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room temperature until used for SELDI-TOF-MS analy-
sis. A matrix solution [α-cyano-4-hydroxycinnamic acid 
(CHCA)] (Ciphergen Biosystems) was prepared accord-
ing to the manufacturer’s instructions in 50  % volume/
volume ACN and 0.5  % TFA. Before SELDI-TOF-MS 
analysis, 1  µL of 1:2 dilution of saturated CHCA solu-
tion was applied onto each spot and allowed to air dry. 
Chips were read on a PCS4000 ProteinChip reader in an 
m/z (mass to charge ratio) of 1100–30,000. Chips corre-
sponding to the 68 serum samples were read over the day 
of their preparation to limit variability across the time. 
One day was used per experimental condition leading to 
four SELDI-TOF-MS experimental days. Complemen-
tarity observed between the four selected conditions is 
illustrated in Additional file 2: Appendix Figure 2. Stand-
ardization of experimental conditions was carried out 
in an effort to minimize the effects of irrelevant sources 
of fluctuation. Serum samples were applied randomly in 
order to avoid any artefact due to experimental handling. 
Replicates were not applied on the same chip array.
Mass accuracy was calibrated externally using the All-
in-1 Peptide Standard (Ciphergen Biosystems) comple-
mented with cytochrome c (MW: 12360) and myoglobin 
(MW 16951.5). Calibration was carried out according 
to the manufacturer’s instructions and is illustrated in 
Additional file  3: Appendix Figure  3. Pre-processing of 
spectra involving calibration, baseline subtraction, noise 
calculation, spectra alignment and total ion current nor-
malization were completed before statistical analysis. 
Coefficients of normalization were in the range of 0.7–
1.5. Peak detection was performed using ProteinChip 
Biomarker Wizard software 3.0 (BioRad).
2D‑difference gel electrophoresis (2D‑DIGE) analysis
Eleven pools of Proteominer® eluate were constituted 
inside both group, HV and NU, and were separated by 
2D-DIGE. Protein content was determined using Plu-
sONE 2-D Quant Kit (GE Healthcare, Uppsala, Sweden).
Analytical gels
Twenty-five µg of proteins from each pool were labelled 
separately in duplicate with 0.2 nmol of Cy3 or Cy5 dyes 
(GE Healthcare, Diegem, Belgium) for an incubation 
time of 30 min. Internal standard was obtained by pool-
ing equal amounts of proteins (25 µg) of each biological 
sample and labelled with Cy2 (GE Healthcare, Diegem, 
Belgium). Following 30  min of incubation in darkness, 
the labelled samples were quenched with additional 
0.2  µL of 10  mM Lysine (Sigma-Aldrich, Schnelldorf, 
Germany) and submitted to another 10  min incubation 
in darkness. Experimental 2D-gel electrophoresis, image 
acquisition and analysis, and PMF/MS–MS protein iden-
tification protocols were already described in a previous 
study [16]. Briefly, pairs of randomly chosen Cy3 and 
Cy5 samples were mixed and pooled with 25 µg of Cy2-
labeled internal standard for 2D-DIGE experiments. Gels 
were scanned using a Typhoon 9400 Laser scanner (GE 
Healthcare, Piscataway, NJ, USA).
Preparative gels
For protein identification, two preparative gels were loaded 
with 250 µg of unlabeled proteins from either serum sam-
ples of HV and NU patients after Proteominer® process-
ing and with 25  µg of the internal standard. Gels were 
run under the same conditions as analytical gels. Spots of 
interest were excised using an Ettan Spotpicker robot (GE 
Healthcare, Piscataway, NJ, USA). Proteins were digested 
with 20  ng/L of trypsin (Roche, porcine, proteomic 
grade) for 4 h at 37 °C using a Janus Robot (Perkin Elmer, 
Waltham, MA, USA). Resulting peptides were extracted 
and rehydrated in 10 µL of formic acid (1 %). Automated 
spectra acquisition was performed using an Ultraflex II 
MALDI mass spectrometer (Bruker Daltonics, Billerica, 
MA). Peptides identification was managed using Biotools 
v.3.1.software (Bruker Daltonics, Billerica, MA) with an in-
house hosted Mascot v2.2.2 server. Human taxonomy was 
used for database search with 100-ppm mass accuracy. 
Identification was significant for peptide mass fingerprint 
with a P < 0.05 and a Mascot protein score ≥70.
Quantification of hepcidin‑25 in serum samples by LC–MS/
MS
Hepcidin-25 levels of serum samples (35 HV and 33 NU) 
were measured by a LC-chip coupled to a nanoelectro-
spray/ion trap/MS operating in positive mode. Extraction 
procedure, calibration standard preparation, chromato-
graphic and MS parameters were previously described by 
Houbart et  al. [17]. Briefly, serum samples were thawed 
at room temperature and centrifuged during 10  min at 
13,400  rpm. Fifty microlitre of each serum sample were 
added to as solution containing 50 μL of 5 % phosphoric 
acid, 12.5  μL internal standard solution to reach a con-
centration of 10  ng/mL and 12.5  μL of hepcidin solu-
tion or water, depending of the type of sample (standard 
or blank sample, respectively). A Waters Oasis μElution 
WCX 96 well plate was used to prepare the samples for 
analysis. The sorbent was first conditioned by 300  μL 
methanol followed by 300  μL water. The entire sample 
was then transferred in the well and drawn through the 
sorbent with a vacuum manifold. The plate was then 
washed with 200 μL of 25 mM ammonium acetate pH6.8, 
200 μL of H2O/ACN (60:40, v/v/) performed twice. The 
extracts were eluted with 2 ×  50  μL of ACN/H2O/TFA 
(75:25:1, v/v/v). The eluates were then evaporated in a 
vacuum evaporator and reconstituted in 100  μL ACN/
H2O/TFA (33.8:66.2:0.1, v/v/v).
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Immunoprecipitation (hepcidin‑25)
Fifteen µg of anti-hepcidin-25 (ab30760; Abcam, Cam-
bridge, UK) antibodies were coupled with 50 µL of pro-
tein G +  beads overnight at 4  °C. Twenty microlitre of 
serum provided by a NU patient was then incubated with 
beads for 2 h at 4 °C. After several washes with PBS con-
taining 0.1  % of Tween-20, bound fractions were eluted 
with 100  mM acetic acid containing 30  % acetonitrile. 
Unbound (Flowthrough) and bound (Eluate) fractions 
were analyzed on IMAC-Cu2+ arrays by SELDI-TOF-
MS. Non-specific IgG antibodies were used as negative 
controls.
Western‑blotting (complement C6 and S100A9)
Complement C6 and S100A9 proteins were assessed by 
Western blot. Briefly, 2 µL of serum was run on 4–12 % 
NUPAGE Bis–Tris polyacrylamide gels (Invitrogen), 
transferred and incubated with anti-C6 monoclonal anti-
body (dilution 1/2000; ab71942; Abcam) or with anti-
S100A9 polyclonal antibody (dilution 1/1000; sc20173; 
Santa Cruz). We then incubated with a mouse or a rabbit 
secondary antibody (dilution 1/5000; Dako) to detect C6 
or S100A9, respectively. Proteins were revealed with an 
enhanced chemiluminescence detection method accord-
ing to the manufacturer’s instructions (GE Healthcare). 
Band intensities were quantified by ImageQuant LAS 
4000 software (GE Healthcare) and are expressed as pixel 
counts representing integrated signal intensities.
Enzyme‑linked immunosorbent assay
A commercially available sandwich ELISA was used for 
apolipoprotein E (ApoE) quantification in serum accord-
ing to manufacturer’s instructions (Catalog# DAPE00, 
R&D Systems).
Nephelometry
Serum levels of complement C3 and C4 were determined 
by an immunonephelometric method on a BNII neph-
elometer (Dade Behring/Siemens) with specific antibod-
ies (Siemens, Marburg, Germany).
Statistics
Demographic statistics
For quantitative data, differences between groups were 
analyzed using a Mann–Whitney U test. For qualita-
tive data, we used the Yates’ continuity corrected χ2 test. 
P < 0.05 were considered as statistically significant.
Statistical analysis for SELDI‑TOF–MS data
Peak intensities were analysed by two statistical 
approaches, a nonparametric Mann–Whitney U tests 
and a machine-learning algorithm called extra-trees 
[18]. Extra-trees is a decision-tree multivariate analysis 
that estimates the relevance or relative contribution of 
each peak to the classification of 2 groups [18]. The lat-
ter approach allows m/z values to be ranked accord-
ing to their relevance for differentiating NU from HV 
groups based on quantitative estimates of the percent-
age of information (% of info) supplied (see Additional 
file  4: Appendix Table  1). P  <  0.05 were considered as 
statistically significant. Q values were calculated using 
FDR (1000 permutations) for multiple testing. The most 
important biomarkers were corrected for age, gender, 
smoking status, consumption of alcohol and the presence 
of pulmonary diseases by a multivariate analysis per-
formed on the SAS software version 9.4.
Statistical analysis for 2D‑DIGE
Two dimensional-gel images were analysed using Decy-
der 2D differential analysis software (v.6.5, GE Health-
care). The differentially expressed proteins in HV vs NU 
were detected using biological variance analysis (BVA) 
module. The unpaired student’s t test was used and a 
P  <  0.05 was considered as statistically significant. Pro-
tein spots that showed a significant fold change of at least 
1.2 with a P  <  0.05 (unpaired student’s t test) in HV vs 
NU comparison were submitted to identification.
Statistical analysis for biomarkers validation
Statistical analysis was performed by GraphPad Prism 
software. Protein levels for hepcidin, complement C6, 
S100A9, ApoE, complement C3 and complement C4 in 
serum of HV and NU patients were compared using the 
non-parametric Mann–Whitney test and were expressed 
as median and interquartile range. P  <  0.05 were con-
sidered as statistically significant. P values were also 




SELDI-TOF–MS was used to provide serum protein 
profiles ranging from 1 to 30 kDa for each HV and NU 
patients. Serum samples were applied on ProteinChip 
arrays as crude serum samples but also after equalization 
(removal) of the most abundant proteins (Proteominer® 
kit) for the detection of medium- and low-abundance 
proteins. For the 35 HV and 33 NU, crude serum sam-
ples and Proteominer® eluates were run in duplicate. 136 
spectra were collected on CM10 and IMAC-Cu2+ Pro-
teinChip arrays for each of the four experimental condi-
tions: (1) crude serum on CM10 arrays (pH9); (2) crude 
serum on IMAC-Cu2+ arrays; (3) Proteominer® eluate on 
CM10 (pH9) and (4) Proteominer® eluate on IMAC-Cu2+ 
arrays (Additional file 2: Appendix Figure 2). Biomarker 
Wizard software resolved 157, 188, 167 and 153 peaks for 
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experimental conditions  1–4, respectively. Peak intensi-
ties in the HV group were compared to corresponding 
peak intensities in the NU group. Peaks of similar intensi-
ties were ignored when peaks of different intensities were 
of particular interest. Peaks were then classified accord-
ing to their percentage of importance (% imp), given by 
the extra-trees multivariate analysis, in differentiating 
HV vs NU spectra. A P value and a Q value for each bio-
marker were also calculated. The most relevant biomark-
ers for the four conditions are summarized in Additional 
file 4: Appendix Table 1.
Identification of potential SELDI biomarkers
Table 2 summarizes selected biomarkers that have been 
identified. Figure  1 illustrates these biomarkers in a 
SELDI-TOF–MS gel view spectra collected from at least 
15 HV and 15 NU patients.
Direct protein identification cannot be achieved by 
SELDI-TOF–MS technology as opposed to other MS/
MS approaches. In a first attempt, protein identification 
was performed by introducing sought m/z values in Tagi-
dent website (http://www.web.expasy.org/tagident) and 
therefore getting access to related protein identification. 
Accordingly, m/z values 2191, 2792, 4798 and 15,866 
were introduced in Tagident. Search for protein identi-
fication was run in a molecular weight range of 0.5, 0.5, 
0.1 and 0.01  %, respectively. Hepcidin-20, hepcidin-25, 
PACAP-related peptide (PRP-48) and hemoglobin β sub-
unit were detected as potential related proteins (Table 2; 
Fig.  1). Identification was confirmed for hepcidin-25 
(Fig.  2) by immunodepletion using specific antibodies 
(Fig. 2). Peaks of interest were depleted after immunode-
pletion (see FT-IP hepcidin in Fig. 2). Proteins were then 
eluted from their immune complex and applied on Pro-
teinChip arrays to be analysed by SELDI-TOF-MS (see 
eluate IP hepcidin in Fig. 2). The depletion was only vis-
ible with specific anti-hepcidin-25 and not with negative 
control antibodies. A similar experiment was conducted 
previously to confirm the identification of hemoglobin β 
subunit [19]. Peaks at m/z 7931 (Fig. 1) and 15,866 were 
the doubly (2H+) and singly (1H+) charged forms of 
hemoglobin β subunit (Table  2). Interestingly, glycated 
forms of hemoglobin β subunit, previously characterized 
with MALDI-TOF by Lapolla et  al. [20, 21], could also 
be detected on spectra of atrophic patients. Protonated 
molecules produced by the condensation of one glucose 
molecule on the hemoglobin β subunit could be observed 
at m/z 8033 (Fig. 1) and 16,022 for the doubly (2H+) and 
singly (1H+) charged forms, respectively (Additional 
file 4: Appendix Table 1).
In previous publications, we have extensively 
described the identification of S100A8, S100A9 and its 
isoform S100A9* proteins after proteomic analysis by 
SELDI-TOF-MS [15, 22]. Our longstanding experience 
with these 3 proteins allowed us to confirm their pres-
ence in the NU cohort. Peaks at m/z 5419 and 10,844 
(Fig. 1) were the doubly (2H+) and singly (1H+) charged 
forms of S100A8 (Table  2). Peak at m/z 6346 was the 
doubly (2H+) charged forms of S100A9*. S100A9* vari-
ant results from a translation beginning at amino acid 
residue 5 and acetylation of amino acid residue 6 (Ser 
residue), yielding a calculated mass of 12,691 Da. Mass 
to charge value 13,269 (Fig.  1) corresponds to the oxi-
dized form of S100A9 (Table  2). Other groups [23–27] 
previously identified some biomarkers that were also 
found in our work such as inter-alpha-trypsin inhibitor 
H4 (ITIH4) fragments, complement C3α-chain frag-
ment and apolipoprotein A-I (ApoA1) protein after 
SELDI-TOF-MS proteomic analysis. Indeed, m/z values 
3157, 3179 and 3974 was characterized as ITIH4 (iso-
form 1) fragment 617–644 [26], ITIH4 (isoform 1) frag-
ment 617–644 [adduct Na+] [26] and ITIH4 (isoform 
1) fragment 650–687 [23, 26] (Table  2; Fig.  1). Mass to 
charge values 4282 and 4299 represent ITIH4 (isoform 
2) fragment 617–657 with and without methionine oxi-
dation [23, 24]. Similarly, m/z value 8132 was identified 
as a C-terminal end truncated form of complement C3a 
[25] (Table 2). Finally, ApoA1 protein was related to m/z 
value 28.1 kDa [27] (Table 2; Fig. 1). P values, Q values 
and adjusted P values are summarized in Table 2. After 
correction, it appears that all adjusted P-values for age, 
gender, smoking status, consumption of alcohol and the 
presence of pulmonary diseases remained statistically 
significant except for C3a and ApoA1 that need there-
fore careful consideration.
2D‑DIGE
2D-DIGE was used to provide serum protein pro-
files ranging from 20 to 200  kDa. Eleven pools of Prot-
eominer® eluate were constituted inside both group, 
HV and NU, and were separated by 2D-DIGE. Figure  3 
illustrates one representative 2D-DIGE gel view of NU-
serum samples after Proteominer® processing. From 
analytical gels, about 4500 spots were detected over the 
selected pH range (pH 3–11) and 24 spots were differen-
tially expressed in NU compared to HV controls with a 
P value <0.05 (Table 3). Twenty spots were up-regulated 
in NU whereas four were down-regulated. These bio-
markers are summarized in Table 3 including their iden-
tification, statistical analysis (p value, t test), fold-change 
in expression levels, isoelectric point (pI), molecular 
weights (MW) and Mascott score values obtained by 
MALDI (Peptide mass fingerprinting (PMF) or MS/MS). 
Figure 4 represents semi quantitative graph of spot inten-
sities obtained for each pooled samples. The 3D view is 
the representation of one HV and NU pool.
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Table 2 Characterization of SELDI-TOF-MS biomarkers: P values were obtained according to the non-parametric Mann–
Whitney U test (see also Additional file 4: Appendix Table 1)
m/z MW ID Amino acid sequence Regulation
HV vs. NU P value Q value Adj.  
P value
Hepcidin (P81172)
 2191 2199 Hepcidin‑20 (frag 65–84) ICIFCCGCCHRSKCGMCCKT Up <0.001 0.007 0.023
 2792 2797 Hepcidin‑25 (frag 60–84) DTHFPICIFCCGCCHRSKCGMCCKT Up <0.001 0.004 0.023
PACAP‑related peptide (P18509)
 4798 4800 PRP‑48 (frag 82–129) DVAHGILNEAYRKVLDQLSAGKHLQSLVAR 
GVGGSLGGGAGDDAEPLS
Up <0.001 0.021 0.037
Hemoglobin β subunit (P68871)









Up <0.001 NS NS









Up <0.001 0.020 0.027
S100A8 (P05109) and S100A9 (P06702)




Up <0.001 0.008 0.0002












Up <0.001 0.004 0.0024








Inter‑alpha‑trypsin inhibitor H4 (ITIH4) (Q14624)
 3157 3157 ITIH4 (isoform 1) frag 617–644 NVHSGSTFFKYYLQGAKIPKPEASFSPR Down <0.001 0.007 0.017
 3179 3180 ITIH4 (isoform 1) frag 617–644 
[aduct Na+]
NVHSGSTFFKYYLQGAKIPKPEASFSPR Down <0.001 0.007 0.017
 3974 3972 ITIH4 (isoform 1) frag 650–687 QAGAAGSRMNFRPGVL
SSRQLGLPGPPDVPDHAAYHPF
Down <0.001 0.020
 4282 4282 ITIH4 (isoform 2) frag 617–657 NVHSAGAAGSRMNFRPGVLSSRQLGLPG 
PPDVPDHAAYHPF
Down <0.001 0.015





Complement C3 alpha chain (P01024)
 8132 8132 C3a (frag 672–739) SVQLTEKRMDKVGKYPKELRKCCEDGMRE 
NPMRFSCQRRTRFISLG
EACKKVFLDCCNYITELRRQHA
Down <0.001 0.022 NS
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Crude serum samples cannot be directly applied on 
2D-gel due to the presence of highly abundant proteins 
(albumin and IgG) masking medium to low-abundance 
protein signals. Accordingly, Proteominer® pre-process-
ing was mandatory for digging deeper into the proteome. 
Nevertheless, it was also responsible for protein level 
equalization, therefore limiting fold change variation 
from 1.2 to 3.5-fold when comparing NU to HV groups. 
However, validation of some biomarkers by alternative 
approach described below (Western blotting, ELISA 
and others) confirmed the robustness of our results and 
allowed a better visualization of protein levels in serum 
before pre-processing steps.
Protein validation
Hepcidin quantification was performed by LC–MS/MS 
in serum samples of both groups and a higher expression 
level was observed in NU-serum samples compared to 
HV (P < 0.001) (Fig. 5).
Western blot analysis with specific antibodies was used 
to validate expression changes of two proteins: comple-
ment C6 and S100A9. The integrated signal intensities 
of specific immunoreactive band was quantified for each 
protein, and intensities were compared between NU and 
HV groups. Both proteins showed an increased expres-
sion level in NU compared to HV (P < 0.001). Apolipo-
protein E was quantified using ELISA kit and elevated 
expression level was observed in NU compared to HV 
(P = 0.006). Finally, C3 and C4 complement factors were 
quantified by nephelometry and their expression levels 
were significantly higher in NU compared to HV (0.0024 
and 0.021, respectively). All biomarkers remained sta-
tistically significant after Bonferroni correction when 
comparing intensities in HV vs. NU groups, except for 
C4 complement.
Discussion
Bone formation is controlled by many factors acting 
locally to regulate proliferation, differentiation and activ-
ity of osteoblasts. TGF-β and BMPs, as well as ligands 
of Wnt family are of course very well known effectors of 
bone formation. Several hormones, such as parathyroid 
hormone, steroids but also leptin can affect bone forma-
tion. The role played by leptin on bone remodelling illus-
trates the connection between lipid and bone metabolism 
[28]. To our knowledge, this is the first proteomics study 
investigating the simultaneous expression of serum pro-
teins in patients with atrophic nonunion. Sera of non-
union patients and healthy volunteers were analysed by 
SELDI-TOF–MS and 2D-DIGE proteomics approaches 
using strict quality control criteria and optimized data 
acquisition and preprocessing parameters. Robust sta-
tistical approach by multivariate analysis was associated 
to the univariate approach for mass spectrometry data 
analysis to highlight potential makers. Several biomark-
ers were up-regulated (hepcidin, PACAP-related peptide, 
hemoglobin β subunit, S100A8, S100A9, ApoE and com-
plement C3, C4 and C6) or down-regulated (ITIH4 frag-
ments, C3a, ApoA1 and ApoA-IV) in serum of patients 
with atrophic fracture compared to controls. Some were 
validated according to alternative approaches and drew 
our specific attention. The differential serum proteome 
analysis of patients with atrophic fractures provided new 
insights on systemic protein expression that are linked to 
bone turn-over, inflammation, innate immunity, glyca-
tion and lipid metabolisms.
Table 2 continued
m/z MW ID Amino acid sequence Regulation
HV vs. NU P value Q value Adj.  
P value
Apolipoprotein A–I (P02647)
 28106 28061 ApoA1 (frag 25–267) DEPPQSPWDRVKDLATVYVDVLKDSGRD 
YVSQFEGSALGKQLNLKL
Down <0.001 0.029 NS









Associated Q values were calculated using FDR (1000 permutations) for multiple testing. Adjusted P value for age, gender, smoking status, consumption of alcohol 
and the presence of pulmonary diseases were performed by multivariate analysis on the SAS software version 9.4
m/z mass/charge ratio of the peak detected by SELDI-TOF-MS, MW molecular weight of the related protein or peptide, ID identification of the related protein or 
peptide, NS not significant
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Fig. 1 SELDI‑TOF–MS gel view spectra for samples collected from at least 15 healthy controls and 15 nonunion patients. Illustration of identified 
biomarkers: hepcidin‑25, pituitary adenylate cyclase‑activating polypeptide (PACAP)—related peptide, hemoglobin β subunit, S100A8, S100A9* 
variant, S100A9, inter‑α‑trypsin inhibitor heavy chain H4 (ITIH4), complement factor C3a and apolipoprotein A1. HV healthy volunteers; NU nonun‑
ion patients
Page 10 of 17de Seny et al. J Transl Med  (2016) 14:258 
There are several limitations to this study. The results 
should be considered as preliminary given that the sam-
ple sizes were too small to draw definitive conclusions 
and an independent validation should be performed with 
a new cohort of freshly collected serum samples. Further, 
age, gender, smoking status, consumption of alcohol and 
the presence of pulmonary diseases were significantly 
divergent between HV and NU groups. However after 
correction, it appears that all adjusted P values remained 
statistically significant except for C3a and ApoA1 that 
need therefore careful consideration. Complement C4 
was also not statistically significant after Bonferroni cor-
rection. Nevertheless, this study sheds some light on new 
markers that could slow down bone healing by enhancing 
a persistent and non-resolving inflammatory process.
Increased hepcidin levels were observed by SELDI-
TOF-MS in patients with atrophic nonunion fracture 
compared to healthy volunteers, and were confirmed 
by quantitative MS/MS approach. Hepcidin is an iron-
regulatory hormone that contributes to iron homoeo-
stasis in human organism. In addition to having a role 
in iron regulation, hepcidin contributes to host defense 
and may modulate inflammatory processes [29]. It is 
mainly secreted by hepatocytes, but other tissues and 
cells express hepcidin including the brain, heart, kid-
ney, adipose tissue, monocytes and macrophages [30–
35]. Although iron is the main regulator of hepcidin in 
hepatocytes, inflammation appears to be the dominant 
regulator of hepcidin in monocytes and macrophages 
[29]. Incubation of the cultured monocytes with IL-6 
increased hepcidin expression [36]. Similarly, hepcidin 
may also be induced in inflammatory condition (under 
IL-6 stimulation) in adipose tissue of obese patients 
[30]. In fracture, macrophages are mobilized at the frac-
ture site to remove cell or matrix debris and to regulate 
tissue repair. Further, patients with atrophic nonun-
ion have persistent elevation of the plasma inflamma-
tory cytokines, CRP and IL-6 [2], and the latter could 
be responsible (in part) to the induction of hepci-
din expression in monocytes/macrophages of those 
patients.
Hepcidin itself seems also closely associated with bone 
metabolism by enhancing osteoblastic differentiation of 
MSCs by activating BMP2/Smad and MAP/p38 path-
ways [37], but also by facilitating osteoclast differentia-
tion [38]. If hepcidin appears regulated by inflammatory 
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Fig. 2 Immunodepletion for hepcidin identification. Purification from serum and identification of the protein fragment at m/z value of 2792 as 
hepcidin‑25. Identification by depletion of serum using specific and non specific antibodies followed by elution from the immune complexes. FT 
flow‑through; IP immunoprecipitation
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mediators, it could itself play a role in the osteoblast/
osteoclast differentiation.
Complement pathway is also involved in inflamma-
tion and innate immunity. Patients with atrophic frac-
ture showed higher levels of complement zymogens 
C3, C4 and C6 by 2D-DIGE whereas levels of the active 
form C3a were decreased in SELDI-TOF-MS experi-
ments. Complement system is activated early after 
trauma in response to various stimuli to present a first 
line of defence of innate immunity against pathogen- 
and danger-associated molecular patterns (PAMPs 
and DAMPs). The role of complement to eliminate 
damaged cells is very well known but can be extended 
now to the regulation of cytokines network, coagula-
tion cascade and even in bone repair [39, 40]. Indeed, 
hyper-activation of the complement cascade can lead 
to unfavourable outcome such as delayed fracture 
healing.
During the whole healing phase, complement factors 
are locally expressed to play a regulatory role dedicated to 
a constant cross talk between the bone and the immune 
system. Studies by Schraufstatter et al. and Ignatius et al. 
revealed that C3a and C5a were powerful chemokines for 
mediating MSC and osteoblasts migration [41, 42]. They 
also observed that C3 and C5 were secreted by undif-
ferentiated and differentiated MSC and osteoblasts [43]. 
In our study, we observed a strong decrease of C3a lev-
els in atrophic fracture compared to healthy conditions 
while levels of the related complement zymogen C3 were 
increased in nonunion patients compared to controls. 
Increased expression of C3 was also observed in serum of 
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Fig. 3 Gel master and location of the protein spots picked: contours are protein spots with at least 1.2‑fold expression change (P < 0.05, student 
t‑test) and proteins significantly identified with the Ultraflex II MALDI mass spectrometer and Biotools v.3.1.software with an in‑house hosted Mascot 
v2.2.2 server
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Another proteins family involved in immune response 
is S100 proteins. S100A8 and S100A9 proteins are cal-
cium-binding proteins expressed in the cytoplasm of 
phagocytes. They belong to DAMP proteins acting as 
alarmins and triggering immune and inflammatory 
responses by interacting with receptors such as receptor 
for advanced glycation end products.
(RAGE) and toll-like receptors 4 (TLR4) [45, 46]. 
Increased S100A8 and S100A9 levels were observed by 
SELDI-TOF-MS in patients with atrophic nonunion frac-
ture compared to healthy volunteers, and were confirmed 
by Western-blotting. S100A8 and S100A9 proteins are 
key players in the amplification of inflammatory reaction. 
They are highly up-regulated in various diseases, such as 
sepsis, rheumatoid arthritis, inflammatory bowel disease 
and cancer. Accordingly, these proteins are now well-
recognized as biomarkers of inflammation. S100A8 and 
S100A9 are also associated with cartilage and bone [47]. 
Further, S100A8 produced by activated macrophages 
is also known to stimulate osteoclast differentiation 
and osteoclast function at the site of inflammation in 
experimental arthritis [48]. The authors mentioned that 
S100A8-stimulated osteoclasts contained significantly 
more actin rings per cell that create the acidic environ-
ment crucial for cathepsin K activity, and therefore sug-
gested that S100A8 could enhance the bone resorptive 
capacity per osteoclast.
Diabetes is a well-known risk factor for delayed frac-
ture healing, and elevated AGEs in blood may be a sig-
nificant risk factor for diabetes. Increased expression of 
hemoglobin β-subunit was observed in serum of atrophic 
patients compared to healthy controls. Interestingly, gly-
cated forms of hemoglobin β-subunit, previously char-
acterized with MALDI-TOF by Lapolla et  al. [20, 21], 
could also be detected on spectra of atrophic patients. 
Protein glycation level can provide effective indications 
Table 3 Proteins with at least 1.2-fold expression change (P < 0.05, student t test) in serum of nonunion patients iden-
tified with the Ultraflex II MALDI mass spectrometer and Biotools v.3.l.software with an in-house hosted Mascot v2.2.2 
server
No Master no Protein ID Name P value Fold pI MW Identification Score 
Mascott
1 2951 APOA4_HUMAN Apolipoprotein A–IV 0.005 −3.27 5.28 45371 PMF 78
2 2314 APOE_HUMAN Apolipoprotein E 0.031 1.73 5.65 36246 PMF 93
3 2296 APOE_HUMAN Apolipoprotein E 0.036 1.65 5.65 36246 MS/MS 34
4 2218 APOE_HUMAN Apolipoprotein E 0.037 1.42 5.65 36246 PMF 86
5 2190 APOE_HUMAN Apolipoprotein E 0.028 1.35 5.65 36246 PMF 133
6 1757 ATX3_HUMAN Ataxin‑3 0.011 −1.4 4.81 42097 PMF 57
7 961 C4BPA_HUMAN C4b‑binding protein alpha chain 0.0043 1.31 7.15 69042 PMF and MS/MS 72 and 44
8 956 C4BPA_HUMAN C4b‑binding protein alpha chain 0.034 1.29 7.15 69042 PMF and MS/MS 111 and 62
9 2200 CLUS_HUMAN Clusterin 0.018 1.39 5.89 53031 PMF and MS/MS 70 and 63
10 2131 CLUS_HUMAN Clusterin 0.02 1.22 5.89 53031 PMF and MS/MS 73and101
11 1946 CLUS_HUMAN Clusterin 0.024 1.28 5.89 53031 MS/MS 17
12 3896 CM016_HUMAN Uncharacterized protein C13orf16 0.0079 1.37 4.99 16981 PMF 57
13 432 co3_human Complement C3 0.016 1.25 6.02 188569 PMF 119
14 444 co6_human Complement component C6 0.0029 1.44 6.39 108367 PMF and MS/MS 88 and 17
15 421 co6_human Complement component C6 0.032 1.27 6.37 108369 PMF 76
16 1883 FHR1_HUMAN Complement factor H‑related  
protein 1
0.0012 −1.58 7.38 38766 PMF and MS/MS 55 and 31
17 1874 FHR1_HUMAN Complement factor H‑related  
protein 1
0.04 1.54 7.38 39766 PMF 85
18 974 IGHM_HUM lg mu chain C region 0.018 1.22 6.35 49960 PMF 63
19 1766 IGHM_HUMAN. 
MUCB_HUMAN.
lg mu chain C region. lg mu heavy 
chain disease protein
0.021 1.75 6.35 49960 MS/MS 34
20 1765 K1C10_HUMAN Keratin. Type I cytoskeletal10 0.024 −1.43 5.13 59020 PMF 57
21 1619 PCOC1_HUMAN Procollagen C‑endopeptidase 
enhancer 1
0.05 1.25 7.41 48797 PMF 61
22 427 RMND1_HUMAN Required for meiotic nuclear division 
protein 1 homolog
0.0023 1.34 8.88 51970 PMF 56
23 2528 RN115_HUMAN RING finger protein 115 0.043 1.21 5.39 34252 PMF 60
24 2660 SAMP_HUMAN Serum amyloid P‑component 0.017 1.25 6.1 25485 PMF 87
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of glycemic regulation and possible chronic complica-
tions in diabetes. Glycated hemoglobin (HbA1c) is one of 
the most powerful parameters that reflect average serum 
glucose concentration over a period of 4–8 weeks. HbA1c 
is important for people with diabetes and is highly cor-
related with the risk of developing diabetes-related com-
plications. One of the many organs affected by diabetes 
is bone. In diabetes, the state of the bone is altered, lead-
ing to an increased fracture risk and subsequently delay 
union, and potentially nonunion [49–52]. Although the 
association of hyperglycemia with bone healing compli-
cations has been well documented, little is known about 
glycated mediators that directly affect bone healing. 
AGEs in bone are associated with decreased systemic 
factors on osteoblast functions such as proliferation, dif-
ferentiation and mineralisation but also increased apop-
tosis [53]. AGE-modified collagen is the most studied 
AGE product causing greater collagen stiffness. It should 
be now clarified if glycated hemoglobin β-subunit is play-
ing a role in the non-healing bone fracture or if it is just a 
marker of AGE products.
Increased ApoE levels were observed by 2D-DIGE in 
patients with atrophic nonunion fracture compared to 
healthy volunteers, and were confirmed by ELISA. ApoE 
is the major protein component of several lipoprotein 
classes. It mediates the transport and clearance of lipids 
in plasma [54]. ApoE isoforms are involved in several 
cardiovascular and neurological pathologies [55], and 
recently, a new role for ApoE has emerged as a regula-
tor of bone metabolism [56]. ApoE seems to be required 
for the sufficient uptake of vitamin K into osteoblasts 
and γ-carboxylation of osteocalcin, a marker of bone cell 
metabolism [56]. Alternatively, ApoE may function as a 
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Fig. 4 Comparative analysis of selected protein spot intensities with the BVA module of the Decyder 6.5 software. Spot intensities obtained for each 
pool of healthy volunteers (HV) and nonunion (NU) patients were plotted on a graph. 3‑D images represent the 3D view of selected spots obtained 
from one representative HV and NU pool for each biomarker of interest
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adipogenic differentiation of MSCs by inhibiting the 
canonical Wnt signalling [56]. Similarly, Bartelt et  al. 
demonstrated that ApoE was involved in an inverse regu-
lation of bone mass and fat mass in growing mice [57]. It 
remains that mechanisms by which ApoE regulates bone 
mass need to be clarified.
Finally, decreased ITIH4 levels were observed by 
SELDI-TOF-MS in atrophic nonunion fracture compared 
to healthy volunteers. The inter-α-trypsin inhibitors (ITI) 
are a family of structurally related plasma serine protease 
inhibitors involved in extracellular matrix stabilization by 
covalent linkage to hyaluronic acid [58]. They are secreted 
into the blood by the liver. The ITI family contains multi-
ple proteins made up of a light chain and a variable num-
ber of heavy chains including H4. ITIH4 is present in 
plasma as a single-chain protein that contains a proline-
rich region (PRR), which is readily cleaved by the plasma 
kallikrein giving rise to multiple small peptides [59]. 
ITIH4 fragmentation patterns is closely associated with 
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Fig. 5 Validation of selected biomarkers by alternative approaches: Hepcidin (MS/MS quantification), complement C6 (western blotting), S100A9 
(western blotting), apolipoprotein E (ELISA), Complement C3 (nephelometry) and Complement C4 (nephelometry). Statistical analysis by Mann–
Whitney U test was performed to compare biomarkers intensity in serum of healthy volunteers (HV) vs nonunion (NU) patients. For western blot‑
ting, band intensities were quantified by ImageQuant LAS 4000 software and are expressed as pixel counts representing integrated signal intensities
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in several cancer diseases such as breast or prostate can-
cer [26, 60]. However, fragmentation of ITIH4 is also 
decreased in some pathologies such as pancreatic can-
cer [24, 60], hepatic cirrhosis [61] and osteoporosis [23]. 
Our results are in adequacy with the decreased ITIH4 
fragmentation pattern observed by Bhattacharyya et  al. 
in patients with high bone turnover compared with the 
low/normal turnover controls. They hypothesized that 
the observed decrease of specific ITIH4 fragments was 
related to increased proteolysis, which is associated with 
the increased osteoclastic activity. However ITIH4 frag-
mentation seems to be more related to the proteolytic 
action of kallikrein in serum [59]. The marked decrease 
of ITIH4 fragmentation between nonunion and control 
patients may be attributed to two different reasons: the 
decreased level of ITIH4 or the decreased level of kal-
likrein in serum of nonunion patients. In further studies, 
we will determine why the enhanced or decreased ITIH4 
fragmentation is selective to certain pathologies.
Conclusions
Bones have a lifelong capacity to regenerate thanks to 
a perfect homeostasis between bone remodeling and 
repair. Bone healing in adult relies on an inflammatory 
process enhancing the communication between the 
innate immune system and local cells involved directly in 
the formation of bone. At the fracture site, inflammatory 
cells such as macrophages are mobilized to remove cell 
or matrix debris and to regulate tissue repair. However, 
a persistent or non-resolving inflammatory response may 
also inhibit healing and enhance the destruction of viable 
tissue, or sustain the production of pro-inflammatory 
cytokines that can impair healing. The expression of hep-
cidin or S100A8/S100A9 by myeloid cells and presence of 
complement C3, C4 and C6 could be the result of a long-
standing inflammatory process. AGE products in associ-
ation with a high glucose level in blood also contribute to 
this inflammatory process. The impaired ability to resolve 
the inflammatory cascade and achieve homeostasis as 
observed with impaired bone healing is enhanced under 
many conditions including smoking, obesity, diabetes, 
polytrauma and aging. Recent studies demonstrated that 
blocking macrophage activation using pharmacological 
agents resulted in trends towards increased callus volume 
and bone formation [62]. Further, mice lacking Toll-like 
receptor-4 (TLR-4), one of the primary receptors initi-
ating the innate immune response, showed accelerated 
healing of calvarial defects [63]. Further work is required 
to determine if alterations in the magnitude and timing of 
inflammation could be targeted to improve fracture heal-
ing in at-risk patients.
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